title: Favorable outcome of ischemic stroke in patients pretreated with statins.
abstract: OBJECTIVE
  Statins may be beneficial for patients with acute ischemic stroke. We tested the hypothesis that patients pretreated with statins at the onset of stroke have less severe neurological effects and a better outcome.
  
  
  METHODS
  We prospectively included consecutive patients with ischemic stroke of <24-hour duration. We recorded demographic data, vascular risk factors, Oxfordshire Classification, National Institutes of Health Stroke Scale (NIHSS) score, admission blood glucose and body temperature, cause (Trial of Org 10172 in Acute Treatment [TOAST] criteria), neurological progression at day 3, previous statin treatment, and outcome at 3 months. We analyzed the data using univariate methods and a logistic regression with the dependent variable of good outcome (modified Rankin Scale [mRS] 0 to 1, Barthel Index [BI] 95 to 100).
  
  
  RESULTS
  We included 167 patients (mean age 70.7+/-12 years, 94 men). Thirty patients (18%) were using statins when admitted. In the statin group, the median NIHSS score was not significantly lower and the risk of progression was not significantly reduced. Favorable outcomes at 3 months were more frequent in the statin group (80% versus 61.3%, P=0.059 with the mRS; 76.7% versus 51.8%, P=0.015 with the BI). Predictors of favorable outcome with the BI were: NIHSS score at admission (OR: 0.72; CI: 0.65 to 0.80; P<0.0001), age (OR: 0.96; CI: 0.92 to 0.99; P=0.017), and statin group (OR: 5.55; CI: 1.42 to 17.8; P=0.012).
  
  
  CONCLUSIONS
  Statins may provide benefits for the long-term functional outcome when administered before the onset of cerebral ischemia. However, randomized controlled trials will be required to evaluate the validity of our results.
authors.affiliation: Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. jmarti@hsp.santpau.es
authors.forename: Joan
authors.initials: J
authors.lastname: Martí-Fàbregas
authors.forename: Meritxell
authors.initials: M
authors.lastname: Gomis
authors.forename: Adrià
authors.initials: A
authors.lastname: Arboix
authors.forename: Aitziber
authors.initials: A
authors.lastname: Aleu
authors.forename: Javier
authors.initials: J
authors.lastname: Pagonabarraga
authors.forename: Robert
authors.initials: R
authors.lastname: Belvís
authors.forename: Dolores
authors.initials: D
authors.lastname: Cocho
authors.forename: Jaume
authors.initials: J
authors.lastname: Roquer
authors.forename: Ana
authors.initials: A
authors.lastname: Rodríguez
authors.forename: María Dolores
authors.initials: MD
authors.lastname: García
authors.forename: Laura
authors.initials: L
authors.lastname: Molina-Porcel
authors.forename: Jordi
authors.initials: J
authors.lastname: Díaz-Manera
authors.forename: Josep-Lluis
authors.initials: JL
authors.lastname: Martí-Vilalta
mesh_terms: D000368:Aged; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy*; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018696:Neuroprotective Agents